

Keytruda® (pembrolizumab) - New indication

- On April 22, 2019, Merck announced the FDA approval of Keytruda (pembrolizumab), in combination with Inlyta® (axitinib), for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
- Keytruda is also indicated for melanoma, non-small cell lung cancer, head and neck squamous cell
 cancer, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial
 carcinoma, microsatellite instability-high or mismatch repair deficient solid tumors or colorectal
 cancer, gastric cancer, cervical cancer, hepatocellular cancer, and Merkel cell carcinoma.
- The new indication for Keytruda was based on data from KEYNOTE-426, an open-label study in 861 patients who had not received systemic therapy for advanced RCC. Patients were randomized to receive Keytruda in combination with Inlyta or Sutent® (sunitinib). The main efficacy outcome measures were overall survival (OS) and progression-free survival (PFS).
 - Median OS was not reached in either treatment arm. However, a statistically significant improvement in OS was demonstrated at the pre-specified interim analysis in patients randomized to Keytruda in combination with Inlyta vs. Sutent (Hazard Ratio [HR] 0.53; 95% CI: 0.38, 0.74; p < 0.0001).
 - Median PFS was 15.1 months (95% CI: 12.6, 17.7) and 11.1 months (95% CI: 8.7, 12.5) for Keytruda in combination with Inlyta vs. Sutent, respectively (HR 0.69; 95% CI: 0.57, 0.84; p = 0.0001).
 - In addition, the overall response rate was 59% (95% CI: 54, 64) and 36% (95% CI: 31, 40) for Keytruda in combination with Inlyta vs. Sutent, respectively (p < 0.0001).
- The most common adverse reactions (≥ 20%) with Keytruda use in combination with Inlyta were diarrhea, fatigue/asthenia, hypertension, hepatotoxicity, hypothyroidism, decreased appetite, palmar-plantar erythrodysesthesia, nausea, stomatitis/mucosal inflammation, dysphonia, rash, cough, and constipation.
- The recommended dose of Keytruda for advanced RCC is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks in combination with 5 mg Inlyta orally twice daily until disease progression, unacceptable toxicity, or for Keytruda, up to 24 months in patients without disease progression.
 - When Inlyta is used in combination with Keytruda, dose escalation of Inlyta above the initial 5 mg dose may be considered at intervals of six weeks or longer. Refer to the Inlyta drug label for additional dosing information.
 - Refer to the Keytruda drug label for dosing for all its other indications.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.